Atopic Dermatitis Therapeutics Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Market Dynamics of Atopic Dermatitis Therapeutics Market Analysis

Growth Drivers

  • Rising prevalence of atopic dermatitis fuels, the growth of the atopic dermatitis market 
  • Market demand for atopic dermatitis is driven by a growing need for personalized medicine   

Restraints

  • Expiry of patents or loss of patents restrain the growth of the global atopic dermatitis drugs market. 

Trends

  • Advancement of products transforms the atopic dermatitis market which drives the market.

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Atopic Dermatitis Therapeutics Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Atopic Dermatitis Therapeutics Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxxxxxx
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Segment Performance in The Atopic Dermatitis Market Drug Class Segment Analysis Based on drug class, the market is segmented into Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, and Other Drug Classes. In 2023, the biologics category accounted for the highest proportion, surpassing 40%. Since biologics target the inflammatory mechanisms fueling the illness rather than merely treating its symptoms, they have a significant therapeutic benefit over traditional topical therapies. These medications have a competitive advantage because of their great specificity. When a patient is resistant to previous systemic therapy, biologics are often administered as second or third-line treatment for severe situations. The increasing need for biologics owing to their high effectiveness, the increase in product approvals, and the availability of a strong pipeline of biologic medications for atopic dermatitis all contribute to the biologics segment's growth. Nemolizumab, a monoclonal antibody that GALDERMA LABORATORIES, L.P. is now developing, is being studied for the potential treatment of atopic dermatitis and pruritus. Due to increased product availability, the PDE4 category is anticipated to rise considerably throughout the projection period. One authorized PDE4 inhibitor is Eucrisa (crisaborole ointment, 2%). In 2016, the FDA gave Pfizer's Eucrisa approval to treat mild-to-moderate Atopic Dermatitis. It has been demonstrated to suppress cytokines generated from Th-2, including TNF-α, IL-10, and IL-2. Pfizer consistently broadens its market penetration and secures fresh authorizations for Eucrisa (crisaborole). For example, the FDA authorized Eucrisa in March 2020 for use in children older than three, expanding the medication's potential to generate income. Rofluminast, a PDE4 that is currently under development, is made by Arcutis Biotherapeutics. The business declared in January 2021 that the medication will begin a phase 3 study. Thus, Because of their innovative approach, biologics are the fastest-growing sector in the market for drugs for atopic dermatitis. With their precise targeting and enhanced potency, monoclonal antibodies and other biologics particularly target the immunological mechanisms that underlie atopic dermatitis. In extreme conditions when standard therapies might not be sufficient, biologics have altered care with significant research investments and positive clinical outcomes. The industry's dedication to developing therapeutic alternatives beyond traditional therapies is seen in the increasing adoption of biologics. Biologics are the foundation of creative and successful atopic dermatitis treatments because of their capacity to modify the immune system, which has a long-lasting and focused effect and propels their explosive rise in the market.

Corticosteroids Atopic Dermatitis Therapeutics Market Analysis
XX
Corticosteroids Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Calcineurin Inhibitors Atopic Dermatitis Therapeutics Market Analysis
XX
Calcineurin Inhibitors Market Size 2025
XX %
CAGR
Locked · Full data in paid report
PDE4 Inhibitors Atopic Dermatitis Therapeutics Market Analysis
XX
PDE4 Inhibitors Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Biologics Atopic Dermatitis Therapeutics Market Analysis
XX
Biologics Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Others Atopic Dermatitis Therapeutics Market Analysis
XX
Others Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape: The Atopic Dermatitis Market

The market for atopic dermatitis is quite competitive worldwide. This is linked to an increase in the burden or prevalence of atopic dermatitis worldwide; thus, market participants are concentrating on introducing innovative products. The anticipated launch of novel products throughout the forecast period is expected to fuel competitive rivalry in the market, which is projected to stay high during that period. Players are increasingly working together, and alliances are being established to create and market new goods. The market's strong profitability during the epidemic is drawing new competitors with creative ideas, making it more competitive for already established businesses. 
Some of the key players in the global atopic dermatitis market are Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.
For instance, in September 2022, Ducentis BioTherapeutics was purchased by Arcutis Biotherapeutics, a US-based commercial-stage biopharmaceuticals business, for an unknown sum. Through the acquisition, Arcutis would be able to fulfill its goal of becoming the market leader in medical dermatology and provide drugs to address patients' unmet dermatological requirements. A US-based preclinical-stage biotechnology startup called Ducentis BioTherapeutics is working on lead indications for atopic dermatitis. 
Source:(https://www.arcutis.com/arcutis-announces-acquisition-of-ducentis-biotherapeutics-ltd/)

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Abbvie Inc••• ••• ••• •••
Bayer AG••• ••• ••• •••
Allergan PLC••• ••• ••• •••
Novartis AG••• ••• ••• •••
Astellas Pharma Inc.••• ••• ••• •••
GALDERMA LABORATORIES••• ••• ••• •••
L.P.••• ••• ••• •••
F. Hoffmann-La Roche Ltd.••• ••• ••• •••
Bausch Health Companies Inc••• ••• ••• •••
Nestle SA••• ••• ••• •••
Pfizer Inc••• ••• ••• •••
AstraZeneca••• ••• ••• •••
Regenron Pharmaceutical Inc••• ••• ••• •••
Evelo Biosciences••• ••• ••• •••
Cara Therapeutics••• ••• ••• •••
Bristol-Myers Squibb Company••• ••• ••• •••
GlaxoSmithKline PLC••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, The Atopic Dermatitis Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. 
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Atopic Dermatitis Market held the highest market revenue share in 2024.

Introduction of The Atopic Dermatitis Market

The skin disease known as atopic dermatitis produces dry, itchy, and inflammatory skin. Though it can occur at any age, small children are most likely to experience it. Atopic dermatitis is a long-term illness that occasionally flares up. It's not contagious, although it can be bothersome.
Atopic dermis often begins in childhood and might get worse as people get older. Atopic dermatitis is an inflammatory skin condition that is caused by changes in immunologic, genetic, pharmacological, and environmental variables. It can be chronic or recurrent. Asthma and allergic rhinitis are common co-occurring atopic illnesses that initially manifest as atopic dermatitis (40–60% of the cases), as per a phenomenon called the atopic march. It is among the most common skin conditions, with lifetime incidence rates of 1-3% for adults and 15-20% for children worldwide.
The American Journal of Managed Care reports that atopic dermatitis affects up to 15 million people in the country. Ten to twenty percent of newborns will develop atopic dermatitis. But as they become older, nearly half of them outgrow it or get much better. Atopic dermatitis affects people of both sexes equally and is more common in people who have a personal or family history of asthma, environmental allergies, or food allergies. Anywhere on the skin could experience atopic dermatitis symptoms. It commonly affects the hands, inner elbows, neck, foot, knees, ankle, and area surrounding the eyes in both children and adults.
Due to their allergies, which include those that can lead to morbidities like asthma and allergic rhinitis, the patient is highly susceptible. There's a chance the condition will become chronic and that it will sometimes get worse and spread. Acne is treated using atopic dermatitis drugs, such as atopic eczema steroids, which also reduce inflammation and other problems caused by the condition.67% of children who commonly have sleep problems have atopic dermatitis. Children's growth may be hampered by sleep deprivation. They also suffer from food allergies, allergic rhinitis, and asthma. Usually starting in infancy, atopic dermatitis develops into additional allergic disorders as people age. These elements drive the market for atopic dermatitis.
Biologic therapy for atopic dermatitis has had a good response. Overall quality of life has increased as a result of these interventions. As a result, there is a noticeable increase in demand for biologic medications for treating atopic dermatitis, and this trend is probably going to continue in the coming years.
One of the main reasons propelling the growth of the atopic dermatitis treatment market is the rise in the incidence of atopic dermatitis among people worldwide. The market for atopic dermatitis therapies is expanding faster than it would otherwise due to rising public knowledge of the disease's treatment options and an increase in government attempts to offer better, more accessible care. The market for treatments for atopic dermatitis is further influenced by the existence of advantageous reimbursement policies and the growth in popularity of these therapies due to digital ads. Additionally, the market for treatments for atopic dermatitis is favourably impacted by the aging population, advancements in healthcare infrastructure, and rising healthcare costs. 
 

Analyst Conclusion

With the help of the above study about the Atopic Dermatitis Market, it can be concluded that the market for Atopic Dermatitis worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Atopic Dermatitis Therapeutics Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Abbvie Inc, Bayer AG, Allergan PLC, Novartis AG, Astellas Pharma Inc., GALDERMA LABORATORIES, L.P., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc, Nestle SA, Pfizer Inc, AstraZeneca, Regenron Pharmaceutical Inc, Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, GlaxoSmithKline PLC and others are profiled in the report.
Segments include Drug Class , End User and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Atopic Dermatitis Therapeutics Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Drug Class Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others
End User Hospitals, Research Lab, Clinics
Route of AdministrationTopical, Injectable, Oral
List of CompetitorsAbbvie Inc, Bayer AG, Allergan PLC, Novartis AG, Astellas Pharma Inc., GALDERMA LABORATORIES, L.P., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc, Nestle SA, Pfizer Inc, AstraZeneca, Regenron Pharmaceutical Inc, Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, GlaxoSmithKline PLC

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Atopic Dermatitis Therapeutics Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Abbvie Inc
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Bayer AG
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Allergan PLC
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Novartis AG
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Astellas Pharma Inc.
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 GALDERMA LABORATORIES
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 L.P.
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 F. Hoffmann-La Roche Ltd.
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Bausch Health Companies Inc
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Nestle SA
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 Financials (Subject to data availability)
        • 1.2.10.4 R&D Investment (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Pfizer Inc
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 Financials (Subject to data availability)
        • 1.2.11.4 R&D Investment (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 AstraZeneca
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 Financials (Subject to data availability)
        • 1.2.12.4 R&D Investment (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis
      • 1.2.13 Regenron Pharmaceutical Inc
        • 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.13.2 Business Overview
        • 1.2.13.3 Financials (Subject to data availability)
        • 1.2.13.4 R&D Investment (Subject to data availability)
        • 1.2.13.5 Product Types Specification
        • 1.2.13.6 Business Strategy
        • 1.2.13.7 Recent Developments
        • 1.2.13.8 Management Change
        • 1.2.13.9 S.W.O.T Analysis
      • 1.2.14 Evelo Biosciences
        • 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.14.2 Business Overview
        • 1.2.14.3 Financials (Subject to data availability)
        • 1.2.14.4 R&D Investment (Subject to data availability)
        • 1.2.14.5 Product Types Specification
        • 1.2.14.6 Business Strategy
        • 1.2.14.7 Recent Developments
        • 1.2.14.8 Management Change
        • 1.2.14.9 S.W.O.T Analysis
      • 1.2.15 Cara Therapeutics
        • 1.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.15.2 Business Overview
        • 1.2.15.3 Financials (Subject to data availability)
        • 1.2.15.4 R&D Investment (Subject to data availability)
        • 1.2.15.5 Product Types Specification
        • 1.2.15.6 Business Strategy
        • 1.2.15.7 Recent Developments
        • 1.2.15.8 Management Change
        • 1.2.15.9 S.W.O.T Analysis
      • 1.2.16 Bristol-Myers Squibb Company
        • 1.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.16.2 Business Overview
        • 1.2.16.3 Financials (Subject to data availability)
        • 1.2.16.4 R&D Investment (Subject to data availability)
        • 1.2.16.5 Product Types Specification
        • 1.2.16.6 Business Strategy
        • 1.2.16.7 Recent Developments
        • 1.2.16.8 Management Change
        • 1.2.16.9 S.W.O.T Analysis
      • 1.2.17 GlaxoSmithKline PLC
        • 1.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.17.2 Business Overview
        • 1.2.17.3 Financials (Subject to data availability)
        • 1.2.17.4 R&D Investment (Subject to data availability)
        • 1.2.17.5 Product Types Specification
        • 1.2.17.6 Business Strategy
        • 1.2.17.7 Recent Developments
        • 1.2.17.8 Management Change
        • 1.2.17.9 S.W.O.T Analysis

  • Chapter 2. Global Atopic Dermatitis Therapeutics Market Analysis

    • 2.1 Global Atopic Dermatitis Therapeutics Market Analysis
    • 2.2 Global Atopic Dermatitis Therapeutics Market Analysis by Region
    • 2.3 Global Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 2.4 Global Atopic Dermatitis Therapeutics Market Analysis by End User
    • 2.5 Global Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 2.6 Global Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 3. North America Atopic Dermatitis Therapeutics Market Analysis

    • 3.1 North America Atopic Dermatitis Therapeutics Market Analysis
    • 3.2 North America Atopic Dermatitis Therapeutics Market Analysis by Country
    • 3.3 North America Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 3.4 North America Atopic Dermatitis Therapeutics Market Analysis by End User
    • 3.5 North America Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 3.6 North America Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 4. Europe Atopic Dermatitis Therapeutics Market Analysis

    • 4.1 Europe Atopic Dermatitis Therapeutics Market Analysis
    • 4.2 Europe Atopic Dermatitis Therapeutics Market Analysis by Country
    • 4.3 Europe Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 4.4 Europe Atopic Dermatitis Therapeutics Market Analysis by End User
    • 4.5 Europe Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 4.6 Europe Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 5. Asia Pacific Atopic Dermatitis Therapeutics Market Analysis

    • 5.1 Asia Pacific Atopic Dermatitis Therapeutics Market Analysis
    • 5.2 Asia Pacific Atopic Dermatitis Therapeutics Market Analysis by Country
    • 5.3 Asia Pacific Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 5.4 Asia Pacific Atopic Dermatitis Therapeutics Market Analysis by End User
    • 5.5 Asia Pacific Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 5.6 Asia Pacific Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 6. South America Atopic Dermatitis Therapeutics Market Analysis

    • 6.1 South America Atopic Dermatitis Therapeutics Market Analysis
    • 6.2 South America Atopic Dermatitis Therapeutics Market Analysis by Country
    • 6.3 South America Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 6.4 South America Atopic Dermatitis Therapeutics Market Analysis by End User
    • 6.5 South America Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 6.6 South America Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 7. Middle East Atopic Dermatitis Therapeutics Market Analysis

    • 7.1 Middle East Atopic Dermatitis Therapeutics Market Analysis
    • 7.2 Middle East Atopic Dermatitis Therapeutics Market Analysis by Country
    • 7.3 Middle East Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 7.4 Middle East Atopic Dermatitis Therapeutics Market Analysis by End User
    • 7.5 Middle East Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 7.6 Middle East Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 8. Africa Atopic Dermatitis Therapeutics Market Analysis

    • 8.1 Africa Atopic Dermatitis Therapeutics Market Analysis
    • 8.2 Africa Atopic Dermatitis Therapeutics Market Analysis by Country
    • 8.3 Africa Atopic Dermatitis Therapeutics Market Analysis by Drug Class
    • 8.4 Africa Atopic Dermatitis Therapeutics Market Analysis by End User
    • 8.5 Africa Atopic Dermatitis Therapeutics Market Analysis by Route of Administration
    • 8.6 Africa Atopic Dermatitis Therapeutics Market Analysis by Key Players

  • Chapter 9. Drug Class Analysis

    • 9.1 Corticosteroids
      • 9.1.1 Global Corticosteroids Market
      • 9.1.2 Global Corticosteroids Market by Region
    • 9.2 Calcineurin Inhibitors
      • 9.2.1 Global Calcineurin Inhibitors Market
      • 9.2.2 Global Calcineurin Inhibitors Market by Region
    • 9.3 PDE4 Inhibitors
      • 9.3.1 Global PDE4 Inhibitors Market
      • 9.3.2 Global PDE4 Inhibitors Market by Region
    • 9.4 Biologics
      • 9.4.1 Global Biologics Market
      • 9.4.2 Global Biologics Market by Region
    • 9.5 Others
      • 9.5.1 Global Others Market
      • 9.5.2 Global Others Market by Region

  • Chapter 10. End User Analysis

    • 10.1 Hospitals
      • 10.1.1 Global Hospitals Market
      • 10.1.2 Global Hospitals Market by Region
    • 10.2 Research Lab
      • 10.2.1 Global Research Lab Market
      • 10.2.2 Global Research Lab Market by Region
    • 10.3 Clinics
      • 10.3.1 Global Clinics Market
      • 10.3.2 Global Clinics Market by Region

  • Chapter 11. Route of Administration Analysis

    • 11.1 Topical
      • 11.1.1 Global Topical Market
      • 11.1.2 Global Topical Market by Region
    • 11.2 Injectable
      • 11.2.1 Global Injectable Market
      • 11.2.2 Global Injectable Market by Region
    • 11.3 Oral
      • 11.3.1 Global Oral Market
      • 11.3.2 Global Oral Market by Region

  • Chapter 12. Qualitative Analysis (Subject to Data Availability)

    • 12.1 Market Drivers
    • 12.2 Market Restraints
    • 12.3 Market Trends
    • 12.4 Market Opportunity
    • 12.5 Technological Road Map (Subject to Data Availability)
    • 12.6 Product Life Cycle (Subject to Data Availability)
    • 12.7 Customer and Buyer Behavior Analysis
      • 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 12.7.4 Pricing, Affordability & Value Perception Analysis
      • 12.7.5 Customer Segmentation & Demand Pattern Analysis
    • 12.8 PESTEL Analysis
      • 12.8.1 Political Factors
      • 12.8.2 Economic Factors
      • 12.8.3 Social Factors
      • 12.8.4 Technological Factors
      • 12.8.5 Legal Factors
      • 12.8.6 Environmental Factors
    • 12.9 Industrial Chain Analysis (Subject to Data Availability)
      • 12.9.1 Industry Chain Analysis
      • 12.9.2 Manufacturing Cost Analysis
      • 12.9.3 Supply Side Analysis
        • 12.9.3.1 Raw Material Analysis
        • 12.9.3.2 Raw Material Procurement Analysis
        • 12.9.3.3 Raw Material Price Trend Analysis
    • 12.10 Porter’s Five Forces Analysis
      • 12.10.1 Bargaining Power of Suppliers
      • 12.10.2 Bargaining Power of Buyers
      • 12.10.3 Threat of New Entrants
      • 12.10.4 Threat of Substitutes
      • 12.10.5 Degree of Competition
    • 12.11 Patent Analysis (Subject to Data Availability)
    • 12.12 ESG Analysis
    • 12.13 Geopolitical Outlook
      • 12.13.1 Global Power Realignment & Strategic Alliances
      • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 12.13.3 International Trade Relations & Market Access Environment
      • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 12.13.6 Technology Sovereignty & Digital Geopolitics
      • 12.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 12.14 AI & Market Transformation
      • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 12.14.2 AI-Driven Transformation of Industry Value Chain
      • 12.14.3 Evolution of Business Models & Revenue Streams
      • 12.14.4 AI-Driven Product, Service & Innovation Transformation
      • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 13. TOP 10 Country Analysis

    • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Atopic Dermatitis Therapeutics Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 17+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Atopic Dermatitis Therapeutics Market

In February 2023, the supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib) was approved by the FDA, expanding the drug's indication to include adolescents (12 to 18 years old) with refractory, moderate-to-severe atopic dermatitis.
Source:(https://www.pharmaceutical-technology.com/news/pfizers-cibinqo-atopic-dermatitis/)

In February 2023, The ADORING 1 and 2 Phase 3 clinical trials using VTAMA (taping of) cream, 1% for the topical treatment of atopic dermatitis Atopic Dermatitis in adults and children as young as two years old have concluded patient recruitment, according to Dermavant Sciences. 
Source:(https://dermavant.com/dermavant-presents-new-data-on-treatment-of-patients-with-skin-of-color-from-adoring-1-and-adoring-2/)

In January 2023, The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) approved Dupixent (dupilumab), and Sanofi has announced that this medication is now recommended for wider EU authorization to treat severe atopic dermatitis in children aged six months to five years who are candidates for systemic therapy. 
Source:(https://www.sanofi.com/en/media-room/press-releases/2023/2023-01-27-06-00-00-2596599#:~:text=The%20European%20Medicines%20Agency's%20Committee,are%20candidates%20for%20systemic%20therapy.)

In January 2023, Sun Pharma, the leading pharmaceutical company in India based on market share, increased its presence in the US dermatological market by purchasing Concert Pharmaceuticals, Inc. (Concert) for $576 million.
Source:(https://www.reuters.com/markets/deals/indias-sun-pharma-acquire-us-based-concert-576-mln-2023-01-19/#:~:text=Jan%2019%20(Reuters)%20%2D%20Sun,drug%20for%20treating%20patchy%20baldness)

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Atopic Dermatitis Therapeutics Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the atopic dermatitis therapeutics market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.